An amended ownership statement for Douglas Forsyth, a director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), was filed on September 18, 2026, restating a June 4, 2026 original to correct the number of stock options reported due to an administrative error.
Key Highlights
- Reporting person: Douglas Forsyth, identified as a Director of Inhibrx Biosciences, Inc.
- Transaction date: June 3, 2026, with the original filing dated June 4, 2026.
- Grant corrected: The amended filing restates the number of stock options granted as 10,000, correcting an administrative error in the original.
- Option terms: Exercise price of $95.22 per share, with the option expiring June 3, 2036.
- Vesting condition: The option becomes fully exercisable on June 3, 2027, subject to the reporting person's continued service through that date.
- Post-transaction holding: Forsyth beneficially owns 10,000 derivative securities following the reported transaction, held directly.
- Price of derivative security: $0, as reported in the filing.
Director Option Grant at Inhibrx Biosciences Restated to Fix Option Count
According to the amended filing, Douglas Forsyth, serving as a director of Inhibrx Biosciences, Inc., received a stock option grant on June 3, 2026 covering the right to purchase shares of the company's common stock. Inhibrx Biosciences is a biosciences company headquartered in La Jolla, California, at 11025 North Torrey Pines Road. The filing was signed by Kelly D. Deck as attorney-in-fact for Douglas G. Forsyth and submitted on September 18, 2026.
The amendment, classified as transaction code "A" (acquisition), reports a grant of 10,000 stock options at an exercise price of $95.22, with an expiration date of June 3, 2036. The filing states that the option "will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date." The price of the derivative security is listed as $0, and the options are held directly by Forsyth. Following the reported transaction, his total beneficial ownership of derivative securities stands at 10,000.
The filing explains the reason for the amendment explicitly: "This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error." No other changes to the terms of the grant are indicated in the amended filing, and no non-derivative securities transactions were reported in Table I.
What Was Disclosed
The amended filing discloses a corrected stock option grant of 10,000 shares to director Douglas Forsyth, with an exercise price of $95.22 and a vesting date of June 3, 2027, filed to fix an administrative error in the original June 4, 2026 submission.



Please wait processing your request...